Eli Lilly has embarked on an aggressive acquisition strategy in 2026, announcing more than $10 billion upfront with potential payouts reaching up to $25 billion across eight deals already this year—a stark departure from the Indianapolis-based drugmaker's historical preference for smaller, early-stage bets. Jacob Van Naarden, who runs Lilly's oncology business and serves as head of corporate business development, told investors and analysts at the American Society of Clinical Oncology annual meeting that the company's financial strength, driven primarily by its GLP-1 franchise, has created what he described as an almost generational opportunity to redeploy capital across new therapeutic areas.
Market Context
Lilly's market capitalization now stands at approximately $1 trillion, making it the first healthcare company to join a club traditionally dominated by technology giants. The company's valuation has surged from roughly $190 billion in 2021, according to LSEG data. This dramatic expansion has fundamentally altered how Lilly approaches dealmaking, shifting from a riskier but inexpensive early-stage investment philosophy toward acquiring more de-risked experimental drugs that carry commensurately higher price tags. The pharmaceutical sector has witnessed broader consolidation trends, with competitors pursuing similar strategies to replenish pipelines facing patent cliffs on blockbuster drugs.
Analysis
Van Naarden's expanded role—added last fall by CEO Dave Ricks to sharpen Lilly's dealmaking capabilities—reflects the company's intentional pivot toward larger, more mature assets. The Centessa Pharmaceuticals acquisition announced in March exemplifies this approach, with potential value reaching up to $7.8 billion if certain development milestones are achieved for experimental sleep disorder treatments including narcolepsy therapies. That would mark Lilly's second-largest deal ever, trailing only the $8 billion Loxo Oncology acquisition in 2019, where Van Naarden served as chief operating officer. While deals of this magnitude remain smaller than those executed by Pfizer or Merck, they represent a meaningful escalation for Lilly and signal willingness to pursue transformative opportunities regardless of therapeutic category.
The company's three recent vaccine company acquisitions demonstrate Lilly's willingness to venture outside its established pillars of oncology, neuroscience, cardiometabolic health, and immunology. Van Naarden hinted at additional moves beyond these core areas during ASCO comments, stating: "We're looking at all kinds of things that don't neatly fit into one of those four buckets, so don't be surprised if we have more to come." When pressed on what might be off-limits, he responded simply: "No, not really."
Key Numbers
- $10 billion+ in upfront acquisition spending across 8 deals through mid-2026
- Up to $25 billion in potential total deal value including milestone payments
- Approximately $4 billion spent on roughly 40 deals during full-year 2025
- ~$1 trillion current market capitalization, up from $190 billion in 2021
- Up to $7.8 billion potential value of Centessa Pharmaceuticals acquisition
- $8 billion Loxo Oncology deal remains Lilly's largest acquisition to date (2019)
What to Watch
Traders should monitor upcoming milestone achievements tied to the Centessa deal, which could trigger additional payments and signal management's ability to execute on larger, more complex transactions. Any announcements regarding acquisitions in new therapeutic areas—particularly as Van Naarden suggested moves beyond Lilly's traditional four pillars—will be closely scrutinized for strategic clarity and valuation discipline. The company's second-quarter earnings call may provide updated guidance on deployment of GLP-1 windfall capital and pipeline prioritization. With no apparent ceiling on deal size according to management commentary, market participants will watch whether Lilly pursues transformative opportunities that could rival mega-cap pharmaceutical mergers.
Lilly's willingness to enter new therapeutic domains via M&A marks a significant strategic evolution for a company that spent years methodically building its internal pipeline. The combination of unmatched financial firepower and an explicit open-ended approach to deal targets creates potential for continued market-moving announcements through year-end.